Published in:
01-02-2011
A case of resistance to clopidogrel and prasugrel after percutaneous coronary angioplasty
Authors:
M. Silvano, C. F. Zambon, G. De Rosa, M. Plebani, V. Pengo, M. Napodano, R. Padrini
Published in:
Journal of Thrombosis and Thrombolysis
|
Issue 2/2011
Login to get access
Excerpt
Dual antiplatelet therapy (aspirin and clopidogrel) is the standard therapy to prevent stent thrombosis after percutaneous coronary angioplasty. Clopidogrel is a prodrug which requires two-step activation through oxidative metabolism, involving various cytochrome P-450 (CYP) enzymes [
1]. Carriers of defective alleles for CYP2C19 (*2) and CYP2C9 (*2, *3) have a reduced antiplatelet effect in response to clopidogrel [
2,
3]. In addition, CYP3A4 in vivo activity measured by the erythromycin breath test is significantly correlated with the ability of clopidogrel to inhibit platelet aggregation [
4]. Lastly, it has been reported that omeprazole and atorvastatin—which are inhibitors of CYP2C19 and CYP3A4, respectively—can reduce the effect of clopidogrel in man [
5,
6]. Thus, there is clinical evidence that the activity of at least three cytochromes determines the effectiveness of clopidogrel in vivo. …